Impact of Low-Burden TP53 Mutations in the Management of CLL
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.841630
Abstract: In chronic lymphocytic leukemia (CLL), TP53 abnormalities are associated with reduced survival and resistance to chemoimmunotherapy (CIT). The recommended threshold to clinically report TP53 mutations is a matter of debate given that next-generation sequencing technologies… read more here.
Keywords: low burden; tp53 mutations; impact; tp53 ... See more keywords